Primary motivations for publishing adverse drug reactions.
收藏NIAID Data Ecosystem2026-03-11 收录
数据链接：
官方服务：
资源简介：
Primary motivations for publishing adverse drug reactions.
应用场景：
创建时间：
2019-07-31
相关数据集
FDA Adverse Event Reporting System Public Dashboard
FDA不良事件报告系统公共仪表板是美国食品药品监督管理局(FDA)维护的数据库，用于收集和公开药品、生物制品和医疗器械的不良事件报告。该系统提供实时数据可视化，帮助医疗专业人员、研究人员和公众了解药物安全性和潜在风险。数据库包含来自医疗保健专业人员、消费者和制造商的自愿报告信息。
知名数据库190
A Dataset of Patients Reviews on Doctissimo Forum of the 2017 Levothyrox Scandal in France for the Early Detection of Safety Signals from Social Networks
In France, the Levothyrox case is an extremely mediated pharmacovogilance case which received a lot of media coverage in August 2017 following the change, in March of the same year, of the pharmaceuti
Zenodo2022-12-05 更新10
Risk of drug-induced delirium in older patients- a pharmacovigilance study of FDA adverse event reporting system database
Drug-induced delirium is known risk factors associated with increased morbidity and mortality in older patients. The objective was to evaluate the risk of drug-related delirium in older patients based
Taylor & Francis Group2025-01-02 更新10
Toxicity profiles associated with EGFR-TKIs combined with angiogenesis inhibitors in non-small cell lung cancer: an epidemiological surveillance analysis of the FDA adverse event reporting system
Ongoing studies are evaluating the efficacy and toxicity profiles of combining epidermal growth factor receptor inhibitors (EGFR-TKIs) with antiangiogenic agents in non-small cell lung cancer (NSCLC).
Taylor & Francis Group2025-10-02 更新20
Table_1_Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database.docx
Because of contradictory evidence from clinical trials, the association between angiotensin-converting enzyme inhibitors (ACEIs) and lung cancer needs further evaluation. As such, the current study is
NIAID Data Ecosystem10
